Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants.

MLA

Dauki, Anees M., et al. “Pharmacokinetics, Pharmacodynamics, and Safety of GS-3583, a FLT3 Agonist Fc Fusion Protein, from Single-Ascending-Dose Phase I Study in Healthy Participants.” Clinical and Translational Science, vol. 17, no. 8, Aug. 2024, p. e70011. EBSCOhost, https://doi.org/10.1111/cts.70011.

APA

Dauki, A. M., Rajakumaraswamy, N., Trowe, T., Weng, W., Lin, K.-W., Elboudjwarej, E., Qin, A. R.-R., Schwabe, C., Kuhne, M. R., & Othman, A. A. (2024). Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants. Clinical and Translational Science, 17(8), e70011. https://doi.org/10.1111/cts.70011

Chicago

Dauki, Anees M, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai-Wen Lin, Emon Elboudjwarej, Ann Ran-Ran Qin, Christian Schwabe, Michelle R Kuhne, and Ahmed A Othman. 2024. “Pharmacokinetics, Pharmacodynamics, and Safety of GS-3583, a FLT3 Agonist Fc Fusion Protein, from Single-Ascending-Dose Phase I Study in Healthy Participants.” Clinical and Translational Science 17 (8): e70011. doi:10.1111/cts.70011.